Under the terms of the agreement, Shasun grants Merck the use of its proprietary cross-coupling copper technology (also known as Buchwald technology) to manufacture and commercialize APIs (active pharmaceutical ingredients). The Buchwald cross-coupling technology is one of the popular technologies in the pharmaceutical area allowing increasingly complex new drugs to be manufactured in an efficient and economical way.
Michel Spagnol, chief technology officer of Shasun said: “This is an important milestone for Shasun in making this technology widely accessible and paving the way for further collaborations.”